225 related articles for article (PubMed ID: 1689212)
21. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition of human nasopharyngeal carcinoma in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
Guan E; Zhou TC; Wang JH; Huang PG; Tang WP; Zhao ML; Chen Y; Sun YX
Int J Cell Cloning; 1989 Jul; 7(4):242-56. PubMed ID: 2768842
[TBL] [Abstract][Full Text] [Related]
24. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor.
Muthuswamy SK; Muller WJ
Oncogene; 1995 Jul; 11(2):271-9. PubMed ID: 7542762
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of human trk proto-oncogene product monoclonal antibodies.
Eager KB
Oncogene; 1991 May; 6(5):819-24. PubMed ID: 2052359
[TBL] [Abstract][Full Text] [Related]
26. Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1.
Kern JA; Wakita R; Sliwkowski MX
Cancer Gene Ther; 1999; 6(6):537-45. PubMed ID: 10608350
[TBL] [Abstract][Full Text] [Related]
27. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
28. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
[TBL] [Abstract][Full Text] [Related]
29. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
Ye D; Mendelsohn J; Fan Z
Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
[TBL] [Abstract][Full Text] [Related]
30. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
[TBL] [Abstract][Full Text] [Related]
31. Characterization of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Meenakshi A; Sivakumar N; Kumar RR; Shankar SG; Dean CJ; Modjtahedi H
Hum Antibodies; 1999; 9(3):149-54. PubMed ID: 10690627
[TBL] [Abstract][Full Text] [Related]
32. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI
Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151
[TBL] [Abstract][Full Text] [Related]
33. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
34. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
35. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
36. Isolation of novel EGFR-specific VHH domains.
Gottlin EB; Xiangrong Guan ; Pegram C; Cannedy A; Campa MJ; Patz EF
J Biomol Screen; 2009 Jan; 14(1):77-85. PubMed ID: 19171923
[TBL] [Abstract][Full Text] [Related]
37. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.
Park BW; Zhang HT; Wu C; Berezov A; Zhang X; Dua R; Wang Q; Kao G; O'Rourke DM; Greene MI; Murali R
Nat Biotechnol; 2000 Feb; 18(2):194-8. PubMed ID: 10657127
[TBL] [Abstract][Full Text] [Related]
38. Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2.
Digiesi G; Giacomini P; Fraioli R; Mariani M; Nicotra MR; Segatto O; Natali PG
Hybridoma; 1992 Aug; 11(4):519-27. PubMed ID: 1383128
[TBL] [Abstract][Full Text] [Related]
39. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
40. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A
Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
